Mar 1, 2026 Log in

News

[Tanvex BioPharma, Inc.] Q1 2026 EPS -1.47 NTD

Citation-Grade Primary-source linked Schema.org verified NQ 0 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published Mar 1, 2026 9:00 AM ・ Updated Jun 13, 2026 8:27 AM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

Tanvex BioPharma reported its Q1 2026 financial results, posting an EPS of -1.47 NTD and a net loss of 389 million NTD on revenues of 133 million NTD.

Tanvex BioPharma reported its Q1 2026 financial results, posting an EPS of -1.47 NTD and a net loss of 389 million NTD on revenues of 133 million NTD.

PRIMARY SOURCE PR Times View source Distributor: PR Times
Published: Mar 1, 2026

Company Code: 6541 Company Name: Tanvex BioPharma, Inc. Industry: Biotechnology and Medical Care Year/Quarter: 2026 Q1 Basic Earnings Per Share: -1.47 NTD Operating Revenue: 133 million NTD Net Income After Tax: -389 million NTD

FACT BOX

Source: PR Times
Category: News

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　Mar 1, 2026 9:00 AM — Distributor PR Times
Collected　May 16, 2026 8:00 AM
AI structured & analyzed　May 16, 2026 8:06 AM
Desk-reviewed & published　Mar 1, 2026 9:00 AM

FAQ

What are the key facts in this article?

Tanvex BioPharma reported its Q1 2026 financial results, posting an EPS of -1.47 NTD and a net loss of 389 million NTD on revenues of 133 million NTD.

Where is the primary source?

PR Times: https://openapi.twse.com.tw/financial/twse-fin-6541-2026Q1

When was it published?

Mar 1, 2026

Cite this article — HOW TO CITE

Washin AI News Desk“[Tanvex BioPharma, Inc.] Q1 2026 EPS -1.47 NTD”AI News by Washin Village（和心村）, Mar 1, 2026. https://aeo.washinmura.jp/ai/%E6%B3%B0%E7%A6%8F%E7%94%9F%E6%8A%80%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/en/news/2026-05-15-tanvex-biopharma-inc-q1-2026-eps-1-47-nt

AI CRAWLER ACTIVITY

as of Jul 7, 2026

AI crawler visits to this article (cumulative)Measuring since publication (no visits recorded yet)

Site-wide cumulative

ClaudeBot

bot_visits_summary

4592k

last Jul 7, 2026

GPTBot

bot_visits_summary

3261k

last Jul 7, 2026

Bingbot

bot_visits_summary

2084k

last Jul 7, 2026

Google AI

bot_visits_summary

1648k

last Jul 7, 2026

Applebot

bot_visits_summary

1640k

last Jul 7, 2026

Googlebot

bot_visits_summary

1262k

last Jul 7, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 泰福生技股份有限公司 Back to newsroom (13)

Copied